Skip to content
2000
Volume 11, Issue 6
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

A series of N1-substituted 2,4,5-triphenyl imidazole derivatives was designed, synthesized and evaluated for their p53-MDM2 binding inhibitory activities and anti-proliferative activities in vitro against four human cancer cell lines (PC3, KB, A549 and HCT116). Although logical evaluation revealed weak p53-MDM2 binding inhibitory activities, most of the obtained molecules displayed moderate to potent cytotoxicities against tested cell lines. As a potential lead compound for further optimization, compound 9c was evaluated as the most potent compound against four cell lines and could induce cell cycle arrest at G2/M phase. The binding mode of compound 9f and MDM2 was further studied by docking analysis and the unexpected interaction mode revealed that this series of compounds may take part into a different binding modes as the lead compound Such as Nutlin, which could induce a different mechanism in cancer therapy.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180811666140116214111
2014-07-01
2025-06-23
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180811666140116214111
Loading

  • Article Type:
    Research Article
Keyword(s): 2; 4; 5-triphenyl imidazole; Anti-cancer; Heterocyclic compounds; p53-MDM2 binding
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test